Cargando…
Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity
After the pertussis vaccine had been introduced in the 1940s and was shown to be very successful in reducing the morbidity and mortality associated with the disease, the possibility of improving both vaccine composition and vaccination schedules has become the subject of continuous interest. As a re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863224/ https://www.ncbi.nlm.nih.gov/pubmed/36679846 http://dx.doi.org/10.3390/vaccines11010001 |
_version_ | 1784875282061066240 |
---|---|
author | Szwejser-Zawislak, Ewa Wilk, Mieszko M. Piszczek, Piotr Krawczyk, Justyna Wilczyńska, Daria Hozbor, Daniela |
author_facet | Szwejser-Zawislak, Ewa Wilk, Mieszko M. Piszczek, Piotr Krawczyk, Justyna Wilczyńska, Daria Hozbor, Daniela |
author_sort | Szwejser-Zawislak, Ewa |
collection | PubMed |
description | After the pertussis vaccine had been introduced in the 1940s and was shown to be very successful in reducing the morbidity and mortality associated with the disease, the possibility of improving both vaccine composition and vaccination schedules has become the subject of continuous interest. As a result, we are witnessing a considerable heterogeneity in pertussis vaccination policies, which remains beyond universal consensus. Many pertussis-related deaths still occur in low- and middle-income countries; however, these deaths are attributable to gaps in vaccination coverage and limited access to healthcare in these countries, rather than to the poor efficacy of the first generation of pertussis vaccine consisting in inactivated and detoxified whole cell pathogen (wP). In many, particularly high-income countries, a switch was made in the 1990s to the use of acellular pertussis (aP) vaccine, to reduce the rate of post-vaccination adverse events and thereby achieve a higher percentage of children vaccinated. However the epidemiological data collected over the past few decades, even in those high-income countries, show an increase in pertussis prevalence and morbidity rates, triggering a wide-ranging debate on the causes of pertussis resurgence and the effectiveness of current pertussis prevention strategies, as well as on the efficacy of available pertussis vaccines and immunization schedules. The current article presents a systematic review of scientific reports on the evaluation of the use of whole-cell and acellular pertussis vaccines, in the context of long-term immunity and vaccines efficacy. |
format | Online Article Text |
id | pubmed-9863224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98632242023-01-22 Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity Szwejser-Zawislak, Ewa Wilk, Mieszko M. Piszczek, Piotr Krawczyk, Justyna Wilczyńska, Daria Hozbor, Daniela Vaccines (Basel) Review After the pertussis vaccine had been introduced in the 1940s and was shown to be very successful in reducing the morbidity and mortality associated with the disease, the possibility of improving both vaccine composition and vaccination schedules has become the subject of continuous interest. As a result, we are witnessing a considerable heterogeneity in pertussis vaccination policies, which remains beyond universal consensus. Many pertussis-related deaths still occur in low- and middle-income countries; however, these deaths are attributable to gaps in vaccination coverage and limited access to healthcare in these countries, rather than to the poor efficacy of the first generation of pertussis vaccine consisting in inactivated and detoxified whole cell pathogen (wP). In many, particularly high-income countries, a switch was made in the 1990s to the use of acellular pertussis (aP) vaccine, to reduce the rate of post-vaccination adverse events and thereby achieve a higher percentage of children vaccinated. However the epidemiological data collected over the past few decades, even in those high-income countries, show an increase in pertussis prevalence and morbidity rates, triggering a wide-ranging debate on the causes of pertussis resurgence and the effectiveness of current pertussis prevention strategies, as well as on the efficacy of available pertussis vaccines and immunization schedules. The current article presents a systematic review of scientific reports on the evaluation of the use of whole-cell and acellular pertussis vaccines, in the context of long-term immunity and vaccines efficacy. MDPI 2022-12-20 /pmc/articles/PMC9863224/ /pubmed/36679846 http://dx.doi.org/10.3390/vaccines11010001 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Szwejser-Zawislak, Ewa Wilk, Mieszko M. Piszczek, Piotr Krawczyk, Justyna Wilczyńska, Daria Hozbor, Daniela Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity |
title | Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity |
title_full | Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity |
title_fullStr | Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity |
title_full_unstemmed | Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity |
title_short | Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity |
title_sort | evaluation of whole-cell and acellular pertussis vaccines in the context of long-term herd immunity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863224/ https://www.ncbi.nlm.nih.gov/pubmed/36679846 http://dx.doi.org/10.3390/vaccines11010001 |
work_keys_str_mv | AT szwejserzawislakewa evaluationofwholecellandacellularpertussisvaccinesinthecontextoflongtermherdimmunity AT wilkmieszkom evaluationofwholecellandacellularpertussisvaccinesinthecontextoflongtermherdimmunity AT piszczekpiotr evaluationofwholecellandacellularpertussisvaccinesinthecontextoflongtermherdimmunity AT krawczykjustyna evaluationofwholecellandacellularpertussisvaccinesinthecontextoflongtermherdimmunity AT wilczynskadaria evaluationofwholecellandacellularpertussisvaccinesinthecontextoflongtermherdimmunity AT hozbordaniela evaluationofwholecellandacellularpertussisvaccinesinthecontextoflongtermherdimmunity |